Publikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria de Navarra (9)

2024

  1. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica

  2. Lipid-based nanosystems: the next generation of cancer immune therapy

    Journal of Hematology and Oncology, Vol. 17, Núm. 1

2023

  1. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

2022

  1. Stealth nanoparticles in oncology: Facing the PEG dilemma

    Journal of Controlled Release, Vol. 351, pp. 22-36

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  3. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

    British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285

2020

  1. Quantification of pharmacokinetic profiles of pd-1/pd-l1 antibodies by validated elisas

    Pharmaceutics, Vol. 12, Núm. 6, pp. 1-16

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25